Racial differences in treatment and outcomes among patients with early stage bladder cancer

Cancer

Volumn 116, Issue 1, 2010, Pages 50-56

  Hollenbeck, Brent K ^a,b   Dunn, Rodney L ^b   Ye, Zaojun ^b   Hollingsworth, John M ^b   Lee, Cheryl T ^a   Birkmeyer, John D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bladder cancer; Disparities; Quality of care; Shared frailty models

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; TREATMENT OUTCOME; URINE CYTOLOGY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 74549118873     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24701     Document Type: Article

References (29)

1. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
2. Lee CT, Dunn RL, Williams C, Underwood W, 3rd. Racial disparity in bladder cancer: trends in tumor presentation at diagnosis. J Urol. 2006;176:927-933.
3. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8 suppl):IV-19-IV-25.
4. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early stage lung cancer. N Engl J Med. 1999;341:1198-1205.
5. Taub DA, Hollenbeck BK, Cooper KL, et al. Racial disparities in resource utilization for cystectomy. Urology. 2006;67:288-293.
6. Lucas FL, Stukel TA, Morris AM, Siewers AE, Birkmeyer JD. Race and surgical mortality in the United States. Ann Surg. 2006;243:281-286.
7. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004;351:575-584.
8. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. verview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-IV-18.
9. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at http://seer.cancer.gov/. Accessed on February 1, 2009.
10. Greene FL, Page EL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
11. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-104-IV-117.
12. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95:588-597.
13. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends. J Natl Cancer Inst. 1993;85:1063-1068.
14. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025-1032.
15. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001;93:1822-1823.
16. Weinstock MA, Reynes JF. Validation of cause-of-death certification for outpatient cancers: the contrasting cases of melanoma and mycosis fungoides. Am J Epidemiol. 1998;148:1184-1186.
17. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163:60-61.
18. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001;345:99-106.
19. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
20. Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics. 2004;60: 747-756.
21. Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med. 2003;139:658-665.
22. Liu JH, Zingmond DS, McGory ML, et al. Disparities in the utilization of high-volume hospitals for complex surgery. JAMA. 2006;296:1973-1980.
23. Virnig BA, Baxter NN, Habermann EB, Feldman RD, Bradley CJ. A matter of race: early versus late-stage cancer diagnosis. Health Aff. 2009;28:160-168.
24. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278-285.
25. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA. 2001;286:1228-1230.
26. Heney NM, Nocks BN, Daly JJ, et al. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 1982;54:152-157.
27. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
28. Anderson RT, Sorlie P, Backlund E, Johnson N, Kaplan GA. Mortality effects of community socioeconomic status. Epidemiology. 1997;8:42-47.
29. Manly JJ. Deconstructing race and ethnicity: implications for measurement of health outcomes. Med Care. 2006;44(11 suppl 3):S10-S16.